Gratwohl, A
,
Pfirrmann, M
Zander, A
Kröger, N
Beelen, D
Novotny, J
Nerl, C
Scheid, C
Spiekermann, K
Mayer, J
Sayer, H G
Falge, C
Bunjes, D
Döhner, H
Ganser, A
Schmidt-Wolf, I
Schwerdtfeger, R
Baurmann, H
Kuse, R
Schmitz, N
Wehmeier, A
Th Fischer, J
Ho, A D
Wilhelm, M
Goebeler, M-E
Lindemann, H W
Bormann, M
Hertenstein, B
Schlimok, G
Baerlocher, G M
Aul, C
Pfreundschuh, M
Fabian, M
Staib, P
Edinger, M
Schatz, M
Fauser, A
Arnold, R
Kindler, T
Wulf, G
Rosselet, A
Hellmann, A
Schäfer, E
Prümmer, O
Schenk, M
Hasford, J
Heimpel, H
Hossfeld, D K
Kolb, H-J
Büsche, G
Haferlach, C
Schnittger, S
Müller, M C
Reiter, A
Berger, U
Saußele, S
Hochhaus, A
Hehlmann, R
Article History
Received: 25 March 2015
Revised: 27 August 2015
Accepted: 5 October 2015
First Online: 14 October 2015
Competing interests
: Dr Pfirrmann reports personal fees from Novartis, personal fees from Bristol-Myers Squibb, outside the submitted work; Dr Scheid reports personal fees from Novartis, personal fees from Bristol-Myers Squibb, personal fees from Pfizer, outside the submitted work; Dr Mayer reports other from German CML Study Group, during the conduct of the study; grants and non-financial support from BMS, grants and non-financial support from Novartis, outside the submitted work; Dr Haferlach and Dr Schnittger report other from MLL Munich Leukemia Laboratory, outside the submitted work; and Dr Susanne Schnittger is employed by and partly owns the MLL Munich Leukemia Laboratory; Dr Reiter reports personal fees and other from Novartis, outside the submitted work; Dr Saußele reports grants, personal fees and non-financial support from Bristol-Myers Squibb, grants, personal fees and non-financial support from Novartis, personal fees and non-financial support from Pfizer, personal fees from ARIAD, outside the submitted work; Dr Hochhaus reports grants from Novartis, BMS, ARIAD, Pfizer, outside the submitted work; Dr Hehlmann reports grants from Bundesministerium für Bildung und Forschung (Kompetenznetz Akute und Chronische Leukämien, Grant No. 01G 19980/6), grants from Hoffmann-La Roche, grants from Essex Pharma, grants from AMGEN, during the conduct of the study; grants from Novartis, grants and personal fees from Bristol-Myers Squibb, outside the submitted work. The other authors declare no conflict of interest.